health · 3 outlets · 3 linked reports
mRNA Cancer Vaccines Post Striking Results in Melanoma and Pancreatic Trials
AI-assisted: summaries and questions may be incomplete or incorrect. Verify important details with the linked original reporting.
Summary
- Moderna and Merck's personalized mRNA vaccine (mRNA-4157) advanced to a phase 3 program after a trial showed a 49% cut in melanoma recurrence-or-death and 62% fewer distant metastases when added to pembrolizumab.
- In pancreatic cancer, nearly 90% of patients whose immune systems responded to an individualized mRNA vaccine were still alive up to six years later.
- With 60+ RNA cancer treatments in development, first commercial approvals are expected around 2029.
The question
Personalized mRNA vaccines will transform cancer treatment.
Open this story in Khali
Get Khali on the App Store